Beranda › Eksim
Uji klinis Eksim yang merekrut di AS
28 studi untuk Eksim merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- San Antonio, TX7 studi
- Birmingham, AL6 studi
- Los Angeles, CA5 studi
- San Diego, CA5 studi
- New York City, NY5 studi
- Indianapolis, IN5 studi
- Huntington Beach, CA4 studi
- Miami, FL4 studi
- Washington, DC4 studi
- Santa Clarita, CA4 studi
- Phoenix, AZ4 studi
- Pittsburgh, PA4 studi
- Louisville, KY3 studi
- Santa Monica, CA3 studi
- St. Petersburg, FL3 studi
- Sacramento, CA3 studi
- San Francisco, CA3 studi
- Meridian, ID3 studi
- Little Rock, AR3 studi
- Tampa, FL3 studi
- Cleveland, OH3 studi
Berdasarkan negara bagian
- Alabama6 studi
- Arizona4 studi
- Arkansas4 studi
- California16 studi
- Florida9 studi
- Idaho3 studi
- Illinois3 studi
- Indiana5 studi
- Maryland6 studi
- Michigan3 studi
- Missouri4 studi
- New York7 studi
- North Carolina3 studi
- Ohio5 studi
- Pennsylvania5 studi
- South Carolina5 studi
- Texas11 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07453602Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Menerima pesertaFase 2
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06947993Effects of Treatments on Atopic Dermatitis
Menerima pesertaFase 2Sukarelawan sehat diterima
Usia 2 hingga 50 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT01631617A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Menerima pesertaFase 3
Usia 2 hingga 11 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06807281First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07527923A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Menerima pesertaFase 3
Usia 6 hingga 11 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06807268A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Menerima pesertaFase 2
Usia 18 hingga 64 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07216027Studies of Skin Microbes in Healthy People and in People With Skin Conditions
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 2 hingga 100 · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT00605878Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
Menerima pesertaStudi observasional
Usia 12 hingga 89 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07645820The Impact of Dietary Salt on the Severity of Eczema
Menerima pesertaFase 4Sukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT07447063The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease
Menerima pesertaFase 4Sukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07487831Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis
Menerima peserta
Usia 13 hingga 17 · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT07746427A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
Menerima pesertaFase 3
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07765888A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
Menerima pesertaFase 2/3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07355075A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 28 Agu 2026 · NCT07599813Cardamom and Topical Roseomonas in Atopic Dermatitis
Menerima pesertaFase 2
Usia 2 hingga 100 · Semua jenis kelamin · Diperbarui 13 Agu 2026 · NCT06096857Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.
Menerima pesertaFase 4
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 13 Agu 2026 · NCT07560618A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Menerima pesertaFase 2
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT07037901Sodium in the Skin and Atopic Dermatitis
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 50 ke atas · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT06998446Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
Menerima pesertaFase 1
Usia 6 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT06504160A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Mei 2026 · NCT05995964The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Mei 2026 · NCT06928246Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mar 2026 · NCT07441395Flourish: Exploring the Early Infant Gut Microbiome
Menerima pesertaSukarelawan sehat diterima
0 Months – 3 Months · Semua jenis kelamin · Diperbarui 24 Feb 2026 · NCT07333482Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Des 2025 · NCT00177268Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.